Diabetes, kidney disease and anaemia: Time to tackle a troublesome triad?

International Journal of Clinical Practice

Volumn 61, Issue 2, 2007, Pages 281-289

  Al Khoury, S ^a   Afzali, B ^a   Shah, N ^a   Thomas, S ^a   Gusbeth Tatomir, P ^b   Goldsmith, D ^a   Covic, Adrian ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSERYTHROPOIESIS; HEMATOPOIESIS; HUMAN; HYPERGLYCEMIA; HYPOXIA; INFLAMMATION; INTERSTITIAL NEPHRITIS; IRON METABOLISM; KIDNEY DISEASE; KIDNEY HYPOXIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; RISK FACTOR;

EID: 33847071208     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01259.x     Document Type: Review

References (79)

1. Nutrition: a review of the WHO programme. II. WHO Chron 1972; 26: 195-206.
2. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-10.
3. Merjanian R, Budoff M, Adler S et al. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int 2003; 64: 263-71.
4. Astor BC, Muntner P, Levin A et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-8.
5. Deray G, Heurtier A, Grimaldi A et al. Anemia and diabetes. Am J Nephrol 2004; 24: 522-6.
6. Bosman DR, Winkler AS, Marsden JT et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-9.
7. Piepsz A, Biggi A, Sixt R et al. Symposium on radionuclides in paediatric nephro-urology. Nucl Med Commun 2003; 24: 11-22.
8. Wasen E, Isoaho R, Mattila K et al. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med 2004; 256: 70-8.
9. Gregory CJ, Eaves AC. Human marrow cells capable of erythropoietic differentiation in vitro. definition of three erythroid colony responses. Blood 1977; 49: 855-64.
10. Gregory CJ, Eaves AC. Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood 1978; 51: 527-37.
11. Coresh J, Byrd-Holt D, Astor BC et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16: 180-8.
12. Thomas MC, Tsalamandris C, MacIsaac RJ, Jerums G. Anemia in diabetes. An emerging complication of microvascular disease. Curr Diab Rev 2005; 1: 107-26.
13. Dikow R, Schwenger V, Schomig M, Ritz E. How should we manage anemia in patients with diabetes? Nephrol Dial Transplant 2002; 17(Suppl. 1): 67-72.
14. de KG, Wilmink JM, Rosengarten PC et al. Serum erythropoietin (ESF) titers in anemia of chronic renal failure. J Lab Clin Med 1982; 100: 720-34.
15. Eckardt KU, Kurtz A, Bauer C. Regulation of erythropoietin production is related to proximal tubular function. Am J Physiol 1989; 256: F942-7.
16. Eschbach JW, Kelly MR, Haley NR et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-63.
17. Spivak JL. Serum immunoreactive erythropoietin in health and disease. J Perinat Med 1995; 23: 13-7.
18. Adamson JW, Eschbach J, Finch CA. The kidney and erythropoiesis. Am J Med 1968; 44: 725-33.
19. Thomas MC, MacIsaac RJ, Tsalamandris C et al. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003; 26: 1164-9.
20. Winkler AS, Marsden J, Chaudhuri KR et al. Erythropoietin depletion and anemia in diabetes mellitus. Diabet Med 1999; 16: 813-9.
21. Ishimura E, Nishizawa Y, Okuno S et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 1998; 11: 83-6.
22. Inomata S, Itoh M, Imai H, Sato T. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron 1997; 75: 426-30.
23. Brito PL, Fioretto P, Drummond K et al. Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. Kidney Int 1998; 53: 754-61.
24. Bank N, Aynedjian HS. Progressive increases in luminal glucose stimulate proximal sodium absorption in normal and diabetic rats. J Clin Invest 1990; 86: 309-16.
25. Catrina SB, Okamoto K, Pereira T et al. Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 2004; 53: 3226-32.
26. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-94.
27. Johnson CS, Keckler DJ, Topper MI et al. In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice. stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678-83.
28. Sato T, Selleri C, Anderson S et al. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol 1997; 97: 356-65.
29. Biaggioni I, Robertson D, Krantz S et al. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 1994; 121: 181-6.
30. De Block CE, Van Campenhout CM, De Leeuw IH et al. Soluble transferrin receptor level. a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. Diabetes Care 2000; 23: 1384-8.
31. Marrollo M, Latella G, Melideo D et al. Increased prevalence of Helicobacter pylori in patients with diabetes mellitus. Dig Liver Dis 2001; 33: 21-9.
32. Taft JL, Billson VR, Nankervis A et al. A clinical-histological study of individuals with diabetes mellitus and proteinuria. Diabet Med 1990; 7: 215-21.
33. Boule NG, Haddad E, Kenny GP et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus. a metaanalysis of controlled clinical trials. JAMA 2001; 286: 1218-27.
34. Stevens PE, O'Donoghue DJ, Lameire NR. Anemia in patients with diabetes. unrecognised, undetected and untreated? Curr Med Res Opin 2003; 19: 395-401.
35. Marathias KP, Agroyannis B, Mavromoustakos T et al. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004; 4: 483-6.
36. Gould AB, Goodman S, DeWolf R et al. Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med 1980; 96: 523-34.
37. Koike H, Ito K, Miyamoto M, Nishino H. Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ14,225) on hemodynamics and circulating blood volume in SHR. Hypertension 1980; 2: 299-303.
38. Lawrence IG, Price DE, Howlett TA et al. Erythropoietin and sexual dysfunction. Nephrol Dial Transplant 1997; 12: 741-7.
39. Nieszporek T, Kokot F, Wiecek A et al. Influence of long-term treatment with human recombinant erythropoietin on secretion of hormones regulating carbohydrate metabolism in hemodialyzed patients with chronic uremia. Pol Arch Med Wewn 1995; 94: 488-94.
40. Deicher R, Horl WH. Anemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2003; 12: 139-43.
41. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 2000; 75: S22-6.
42. Grunwald JE, Riva CE, Sinclair SH et al. Laser Doppler velocimetry study of retinal circulation in diabetes mellitus. Arch Ophthalmol 1986; 104: 991-6.
43. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995; 92: 10457-61.
44. Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy. the RENAAL study. Kidney Int 2003; 63: 1499-507.
45. Davis MD, Fisher MR, Gangnon RE et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss. Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998; 39: 233-52.
46. Caravaca F, Arrobas M, Luna E et al. Progression of renal insufficiency in the pre-end-stage renal disease setting. Nefrologia 2003; 23: 510-9.
47. Al-Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955-62.
48. Nikolsky E, Aymong ED, Halkin A et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2004; 44: 547-53.
49. Zeidman A, Fradin Z, Blecher A et al. Anemia as a risk factor for ischemic heart disease. Isr Med Assoc J 2004; 6: 16-8.
50. Carson JL, Duff A, Poses RM et al. Effect of anemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348: 1055-60.
51. Lee PC, Kini AS, Ahsan C et al. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Coll Cardiol 2004; 44: 541-6.
52. Silverberg D, Blum M, Peer G, Iaina A. Anemia during the predialysis period. A key to cardiac damage in renal failure. Nephron 1998; 80: 1-5.
53. Weiner DE, Tighiouart H, Vlagopoulos PT et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005; 16: 1803-10.
54. Sinclair SH. Macular retinal capillary hemodynamics in diabetic patients. Ophthalmology 1991; 98: 1580-6.
55. Thomas MC, Cooper ME, Tsalamandris C et al. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005; 165: 466-9.
56. El-Achkar TM, Ohmit SE, McCullough PA et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency. The Kidney Early Evaluation Program. Kidney Int 2005; 67: 1483-8.
57. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-9.
58. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-35.
59. Al-Khoury S, Afzali B, Shah N, Covic A, Thomas S, Goldsmith DJ. Anaemia in diabetic patients with chronic kidney diseaseprevalence and predictors. Diabetologia 2006; 49: 1183-9. Epub 2006 Apr 12.
60. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl. 2.ii): 1-47.
61. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-85.
62. Jungers P, Choukroun G, Oualim Z et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16: 307-12.
63. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function. a randomized controlled trial. Kidney Int 2004; 66: 753-60.
64. London GM, Zins B, Pannier B et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989; 36: 878-82.
65. Sikole A, Polenakovic M, Spirovska V et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993; 17: 977-84.
66. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. BMJ 1990; 300: 573-8.
67. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anemia in pre-dialysis patients. Cochrane Database Syst Rev CD003266, 2001.
68. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 2003;18(Suppl. 8): viii37-41.
69. Sundal E, Kaeser U. Correction of anemia of chronic renal failure with recombinant human erythropoietin. safety and efficacy of one year's treatment in a European multicentre study of 150 hemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4: 979-87.
70. Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: Rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 2005; 68(Suppl. 1): S22-9.
71. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
72. McMahon LP, Mason K, Skinner SL et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15: 1425-30.
73. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37.
74. Rossert J, Eckardt KU. Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 2005; 20: 1025-8.
75. Silva M, Benito A, Sanz C et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999; 274: 22165-9.
76. Kashii Y, Uchida M, Kirito K et al. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 2000; 96: 941-9.
77. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001; 412: 641-7.
78. Yang CW, Li C, Jung JY et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17: 1754-5.
79. Sekiguchi N, Inoguchi T, Kobayashi K et al. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells. Biochem Biophys Res Commun 2005; 334: 218-22.